News

Hydroxychloroquine doesn’t seem to lower lupus preeclampsia risk

The antimalarial agent hydroxychloroquine doesn’t appear to lower the risk of preeclampsia during pregnancy in women with lupus, a study reports. The study, “Hydroxychloroquine in lupus pregnancy and risk of preeclampsia,” was published in Arthritis & Rheumatology. Preeclampsia is a pregnancy complication marked by high…

Modified immune Tregs show promise in treating lupus nephritis

Modified anti-inflammatory T-regulatory immune cells, known as Tregs, were able to suppress autoimmune activity in cells and in a mouse model of lupus nephritis, a common complication of lupus marked by kidney inflammation, a new study reports. These findings support the development of a Treg-based treatment that uses a…

DNA-bound proteins from NETs predict worse kidney outcomes

DNA-bound proteins released from traps cast by neutrophils, a type of immune cell, may help predict which lupus nephritis patients are most likely to respond to treatment two years after a renal (kidney) flare, a study indicates. Those with higher levels of Elastase-DNA and HMGB1-DNA were…

Longer clinical remission leads to better kidney function: Study

People with lupus nephritis who are in clinical remission, with no symptoms for at least one year, are 82% less likely to experience impaired kidney function than those who do not remain in remission, a study has found. Moreover, longer sustained remission increases the odds of patients staying in remission…

Possible urinary biomarkers of lupus nephritis identified in study

Scientists have identified a number of proteins in the urine with high diagnostic accuracy for identifying kidney involvement in people with systemic lupus erythematosus (SLE). Such biomarkers may enable the earlier identification of lupus nephritis, a serious manifestation of SLE that can cause kidney failure, thus allowing for faster interventions…

New MyLupus mobile phone app aims to help in healthcare decisions

MyLupus, a new mobile phone app that’s meant to be used between doctor visits, was designed to help people with moderate to severe lupus make more-educated healthcare decisions. The free application was developed by a team of scientists — including rheumatologists at the University of Alabama at Birmingham (UAB)…

China clears Phase 1/2 trial of GC012F in difficult-to-treat SLE

China’s regulatory body has given Gracell Biotechnologies the green light to launch a Phase 1/2 clinical trial testing GC012F, an experimental dual-targeting CAR T-cell therapy, in people with difficult-to-treat systemic lupus erythematosus (SLE). The decision by China’s National Medical Products Administration comes shortly after the U.S. Food and…